Related content

CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab

By DiJoseph John   Dougher Maureen   Armellino Douglas   Kalyandrug Lyka   Kunz Arthur   Boghaert Erwin   Hamann Philip   Damle Nitin  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 7, 2007-07 ,pp. : 1107-1117

Springer Publishing Company

Access to resources Recommend Favorite

Transdermal Delivery of 5-Fluorouracil for Induced Ehrlich Ascites Carcinoma Tumor in Balb/c Mice and Pharmacokinetic Study

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 2, Iss. 3, 2007-11 ,pp. : 235-239

Bentham Science Publishers

Access to resources Recommend Favorite

Antibody–drug conjugates (ADCs)—new targeted therapies

By Papakonstantinou Georgios  

memo - Magazine of European Medical Oncology, Vol. 6, Iss. 4, 2013-12 ,pp. : 223-224

Springer Publishing Company

Access to resources Recommend Favorite

Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 9, Iss. 1, 2014-01 ,pp. : 35-65

Bentham Science Publishers

Access to resources Recommend Favorite

Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP

By DiJoseph John   Dougher Maureen   Evans Deborah   Zhou Bin-Bing   Damle Nitin  

Cancer Chemotherapy and Pharmacology, Vol. 67, Iss. 4, 2011-04 ,pp. : 741-749

Springer Publishing Company

Access to resources Recommend Favorite